Key result
The Nobori drug-eluting stent was superior to the Taxus Liberte stent for in-stent late loss at 9 months and noninferior to the Cypher stent for target vessel failure.
Why the study?
Does the biolimus A9-eluting stent (Nobori) improve angiographic and clinical outcomes compared to other drug-eluting stents in patients requiring coronary stenting?
Does the biolimus A9-eluting stent (Nobori) improve angiographic and clinical outcomes compared to other drug-eluting stents in patients requiring coronary stenting?
The Nobori biolimus A9-eluting stent with a biodegradable polymer demonstrates favorable angiographic and clinical outcomes, including low rates of stent thrombosis and target lesion revascularization, compared to earlier generation drug-eluting stents.
Answers are grounded in this paper and cite their sources.
May inform stent selection in practice; leaves open need for confirmatory randomized trials.
Drug-eluting stents with different drugs, polymers and platforms are currently available on the market. Among the stents of novel generation, significant place belongs to the Nobori® drug-eluting stent (Terumo Corporation, Tokyo, Japan), built on a flexible stent platform coated with an antiproliferative drug, biolimus A9™ and biodegradable polymer, with the drug polymer matrix applied on only the abluminal surface. Extensively studied in the comprehensive NOBORI clinical program, the Nobori drug-eluting stent was superior when compared with Taxus® Liberte® stent for in-stent late loss at 9 months, and noninferior to Cypher® stent in terms of target vessel failure. The initial promising results were confirmed in NOBORI 2, a large study of all-comers patient population. Although underpowered for detection of late and very late stent thromboses, the most interesting findings of NOBORI trials are still the very low rates of these events along with the low frequency of target lesion revascularization.
No takes yet. Share an insight, caveat, or question.
Danzi et al. (2012) reported a review. Nobori drug-eluting stent vs. Taxus Liberte stent and Cypher stent was evaluated on In-stent late loss and target vessel failure. The Nobori drug-eluting stent was superior to the Taxus Liberte stent for in-stent late loss at 9 months and noninferior to the Cypher stent for target vessel failure.
Synapse has enriched 10 related papers. Consider them for comparative context: